Results 81 to 90 of about 1,580 (184)

Mavacamten safety and efficacy in a heart transplant patient exhibiting obstructive hypertrophic cardiomyopathy phenotype

Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis.
Tajik, A Jamil, Misicka, Amanda, Abood, Zaid, Ashraf, Muddasir, Peters, Matthew, Galazka, Patrycja, Ghafoor, Asad, Jan, M Fuad, Jahangir, Arshad   +8 more
core   +1 more source

Familial Hypertrophic Cardiomyopathy: Diagnosis and Management

Vascular Health and Risk Management, 2023
Michael J Litt,1 Ayan Ali,2 Nosheen Reza1 1Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; 2Department of Medicine, Perelman School of Medicine at the ...
Litt MJ, Ali A, Reza N
doaj  

Myosin Modulator Aficamten Inhibits Force by Altering Myosin’s Biochemical Activity Without Changing Thick Filament Structure

JACC: Basic to Translational Science
Summary: We investigated the effects of aficamten on cardiac muscle structure, biochemical activity, and contractile function. Aficamten does not structurally sequester myosin heads along the thick filament.
Saffie Mohran, PhD, Kristina B. Kooiker, PhD, Ateeqa Naim, BS, Matvey Pilagov, BS, Anthony Asencio, BS, Kyrah L. Turner, BS, Weikang Ma, PhD, Galina Flint, MD., Siyao Jiang, BS, Jing Zhao, BS, Timothy S. McMillen, PhD, Christian Mandrycky, PhD, Max Mahoney-Schaefer, BS, Thomas C. Irving, PhD, Bertrand C.W. Tanner, PhD, Neil M. Kad, PhD, Michael Regnier, PhD, Farid Moussavi-Harami, MD   +17 more
doaj   +1 more source

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis

Indian Heart Journal
Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).
Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K. Awad   +6 more
doaj   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

, 2019
Mavacamten is a small molecule modulator of cardiac myosin designed as an orally administered drug for the treatment of patients with hypertrophic cardiomyopathy.
Ryan Dick (5566745), Nicole Haste (5806802), Priscilla Brun (5806805), John C. L. Erve (2275543), Timothy J. Carlson (5806808), Svetlana Markova (3545603), Marc Evanchik (5806811), Mark P. Grillo (2413657), James P. Driscoll (2159146)   +8 more
core   +1 more source

Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy – an updated Meta-Analysis of randomized controlled trials

International Journal of Cardiology: Heart & Vasculature
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM.
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar   +11 more
doaj   +1 more source

Mavacamten in Hypertrophic Cardiomyopathy: Unraveling Therapeutic Potential and Clinical Implications in Advancing Cardiovascular Medicine

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypertrophy, often leading to various cardiovascular symptoms and complications.
Ankit Kumar, Prachi Pandey, Dilip Jangid, Sanjeevani Tyagi, Rahul Raj
core  

Mavacamten eligibility in patients with hypertrophic cardiomyopathy attending cardiology clinic in Essex, UK

, 2022
Hypertrophic cardiomyopathy (HCM) is a heart muscle disease with few targeted therapies. Patients with left ventricular outflow tract obstruction (HOCM) are at risk of sudden cardiac death and may experience symptoms of dyspnoea, fatigue, dizziness and ...
Jason Dungu (17463576), Henry Oluwasefunmi Savage (17463453), Brian Li (1468348), Sarina Vara (16677039)   +3 more
core  

Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy

Hypertrophic obstructive cardiomyopathy (HCM) is the most common heterogeneous genetic cardiovascular disorder. Its pathophysiology involves left ventricular hypertrophy, increased fibrosis, hypercontractility, and reduced compliance.
Gupta, Dharmendra, Jakhar, Punam, Kumar, Susheel, Makhija, Mahima, Bansal, Alka, Sharma, Lokendra   +5 more
core   +1 more source